Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.14 +2.0%	$7.04	$3.54 ▼ $8.25	$166.36M	0.87	88,052 shs	1.60 million shs
FATE Fate Therapeutics	$1.04 -5.5%	$1.23	$0.66 ▼ $5.92	$119.18M	2.23	2.21 million shs	3.75 million shs
FDMT 4D Molecular Therapeutics	$3.84 -5.7%	$3.70	$2.24 ▼ $28.93	$177.91M	2.84	812,373 shs	1.44 million shs
OKUR OnKure Therapeutics	$2.40 -4.8%	$2.44	$1.70 ▼ $20.00	$32.42M	0.42	108,864 shs	93,296 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	0.00%	+9.68%	-11.41%	+21.02%	+26.60%
FATE Fate Therapeutics	0.00%	-12.61%	-15.79%	+31.63%	-68.29%
FDMT 4D Molecular Therapeutics	0.00%	-7.02%	+6.37%	+18.89%	-81.71%
OKUR OnKure Therapeutics	0.00%	+1.27%	-3.61%	-44.19%	+239,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	2.1259 of 5 stars	3.5	1.0	0.0	2.4	1.7	0.6
FATE Fate Therapeutics	4.1328 of 5 stars	3.1	3.0	4.7	2.5	1.7	0.6
FDMT 4D Molecular Therapeutics	2.311 of 5 stars	3.3	2.0	0.0	2.6	1.7	0.6
OKUR OnKure Therapeutics	3.3651 of 5 stars	3.7	0.0	0.0	2.2	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	3.00	Buy	$9.50	33.05% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	268.59% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	669.68% Upside
OKUR OnKure Therapeutics	3.33	Buy	$32.33	1,247.22% Upside

Current Analyst Ratings Breakdown

Latest OKUR, DERM, FATE, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	2.96	N/A	N/A	$0.91 per share	7.85
FATE Fate Therapeutics	$13.63M	8.74	N/A	N/A	$2.80 per share	0.37
FDMT 4D Molecular Therapeutics	$40K	4,447.68	N/A	N/A	$11.05 per share	0.35
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$7.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-14.76%	-52.03%	-11.28%	8/11/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$5.26	N/A	N/A	N/A	N/A	-49.13%	-45.72%	8/12/2025 (Estimated)

Latest OKUR, DERM, FATE, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/6/2025	Q1 2025	OKUR OnKure Therapeutics	-$1.41	-$1.19	+$0.22	-$1.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.07	1.34	1.03
FATE Fate Therapeutics	N/A	8.81	8.81
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
OKUR OnKure Therapeutics	N/A	11.18	11.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
FATE Fate Therapeutics	97.54%
FDMT 4D Molecular Therapeutics	99.27%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	15.03%
FATE Fate Therapeutics	5.51%
FDMT 4D Molecular Therapeutics	9.60%
OKUR OnKure Therapeutics	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	11.09 million	N/A

OKUR, DERM, FATE, and FDMT Headlines

Recent News About These Companies

OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives $32.33 Consensus Target Price from Brokerages

June 22, 2025 | americanbankingnews.com

OKUR OnKure Therapeutics, Inc.

June 12, 2025 | seekingalpha.com

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

June 3, 2025 | tipranks.com

Insider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of Stock

May 20, 2025 | insidertrades.com

OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 Shares

May 15, 2025 | insidertrades.com

Major Shareholder Sells Thousands of OnKure Therapeutics Shares!

May 14, 2025 | tipranks.com

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

May 9, 2025 | tipranks.com

OnKure increased R&D spending in 1Q with drug trials underway

May 7, 2025 | bizwest.comB

OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | finanznachrichten.de

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock News

April 30, 2025 | gurufocus.com

OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Charts

April 16, 2025 | nasdaq.com

Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%

April 5, 2025 | aaii.comA

OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright

March 18, 2025 | markets.businessinsider.com

Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025

March 18, 2025 | tipranks.com

Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?

March 12, 2025 | finance.yahoo.com

Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects

March 12, 2025 | tipranks.com

OnKure Therapeutics Reports Progress and Financials

March 11, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

OKUR, DERM, FATE, and FDMT Company Descriptions

Journey Medical NASDAQ:DERM

$7.14 +0.14 (+2.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.62 -0.52 (-7.28%)

As of 04:00 AM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fate Therapeutics NASDAQ:FATE

$1.04 -0.06 (-5.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.04 (+3.85%)

As of 04:04 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

4D Molecular Therapeutics NASDAQ:FDMT

$3.84 -0.23 (-5.65%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.07 +1.23 (+32.03%)

As of 04:00 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

OnKure Therapeutics NASDAQ:OKUR

$2.40 -0.12 (-4.76%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.60 +3.20 (+133.33%)

As of 04:00 AM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time